Zoek in het archief
 
terug

Check the original
News breaking: 2017-10-10

Teva to Report Third Quarter 2017 Financial Results on November 2, 2..


Previous Article
Teva to Report Second Quarter 2017 Fin...
Teva to Report Third Quarter 2017 Financial Results on November 2, 2017
JERUSALEM--(BUSINESS WIRE)--Oct. 10, 2017--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it
will release its third quarter 2017 financial results on Thursday,
November 2, 2017 at 7:00 a.m. ET.
Teva will host a conference call and live webcast on the same day, at
8:00 a.m. ET to discuss its third quarter 2017 results and overall
business environment. A Question & Answer session will follow this
discussion.
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States 1-866-869-2321;
Canada 1-866-766-8269 or International +44(0) 203 0095710; passcode:
91932782. For a list of other international toll-free numbers, click here.
A live webcast of the call will also be available on Teva's website at: www.ir.tevapharm.com
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also
be accessed until November 30, 2017, 9:00 a.m. ET by calling United
States 1-866-247-4222; Canada 1-866-878-9237 or International +44(0)
1452550000; passcode: 91932782.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by approximately 200 million
patients in 100 markets every day. Headquartered in Israel, Teva is the
world’s largest generic medicines producer, leveraging its portfolio of
more than 1,800 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has the
world-leading innovative treatment for multiple sclerosis as well as
late-stage development programs for other disorders of the central
nervous system, including movement disorders, migraine, pain and
neurodegenerative conditions, as well as a broad portfolio of
respiratory products. Teva is leveraging its generics and specialty
capabilities in order to seek new ways of addressing unmet patient needs
by combining drug development with devices, services and technologies.
Teva's net revenues in 2016 were $21.9 billion. For more information,
visit www.tevapharm.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171010006511/en/
Source: Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.IR Contacts:Kevin C.
Mannix, United States, 215-591-8912Ran Meir, United
States, 215-591-3033Tomer Amitai, Israel, 972 (3) 926-7656orPR
Contacts:Iris Beck Codner, Israel, 972 (3) 926-7246Denise
Bradley, United States, 215-591-8974
Share on FacebookShare on LinkedIn